Abbisko Cayman Limited (HKG:2256)

Hong Kong flag Hong Kong · Delayed Price · Currency is HKD
7.83
+0.13 (1.69%)
May 9, 2025, 4:08 PM HKT
128.95%
Market Cap 4.89B
Revenue (ttm) 536.33M
Net Income (ttm) 30.12M
Shares Out 624.70M
EPS (ttm) 0.04
PE Ratio 183.95
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 2,626,850
Average Volume 4,486,677
Open 7.72
Previous Close 7.70
Day's Range 7.60 - 7.95
52-Week Range 2.73 - 8.98
Beta 1.22
RSI 55.43
Earnings Date May 12, 2025

About Abbisko Cayman

Abbisko Cayman Limited, an investment holding company, engages in the research and development of pharmaceutical products in the People’s Republic of China. The company develops Pimicotinib, which is in Phase III clinical trial for the treatment of tenosynovial giant cell tumor; Irpagratinib for the treatment of hepatocellular carcinoma; ABSK043 that is in Phase I clinical trial for the treatment of non-small cells lung cancer; and ABSK061 for the treatment of solid tumors. It also develops Fexagratinib, which is in Phase II clinical trial for ... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2016
Employees 281
Stock Exchange Hong Kong Stock Exchange
Ticker Symbol 2256
Full Company Profile

Financial Performance

Financial numbers in CNY Financial Statements

News

There is no news available yet.